Anika Therapeutics (ANIK) Non-Current Debt (2010 - 2020)

Anika Therapeutics' (ANIK) quarterly Non-Current Debt came in at $25.0 million in Q3 2020, down 50.0% on a QoQ basis from $50.0 million in Q2 2020.

Anika Therapeutics (ANIK) Non-Current Debt (2010 - 2020) Analysis & Trends

Anika Therapeutics (ANIK) has 5 years of Non-Current Debt data on file, last reported at $25.0 million in Q3 2020.

On a quarterly basis, Non-Current Debt changed N/A year-over-year to $25.0 million in Q3 2020; TTM through Sep 2020 was $25.0 million, a N/A change from a year earlier, with the FY2012 full-year figure at $9.6 million, changed 0.0% from the prior year.
Non-Current Debt for Q3 2020 stood at $25.0 million, down from $50.0 million in the prior quarter.
Over the last five years, Non-Current Debt for ANIK reached as high as $50.0 million in Q2 2020 and fell as low as $25.0 million in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-	10.34 Bn
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn	14.02 Bn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn	9.05 Bn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn	27.86 Bn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn	-
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn	12.41 Bn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn	-
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn	3.74 Bn
10	Anika Therapeutics	198.50 Mn	131.71 Mn	19.00 Mn	-

Download Data